| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Congenital Abnormalities | 29 | 2025 | 290 | 9.250 |
Why?
|
| Rhabdomyosarcoma | 22 | 2025 | 209 | 7.560 |
Why?
|
| Neoplasms | 37 | 2025 | 3025 | 5.910 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 43 | 2025 | 809 | 5.810 |
Why?
|
| Registries | 49 | 2025 | 1561 | 5.060 |
Why?
|
| Maternal Exposure | 31 | 2020 | 153 | 5.040 |
Why?
|
| Air Pollutants | 16 | 2025 | 113 | 4.490 |
Why?
|
| Genetic Predisposition to Disease | 47 | 2025 | 3476 | 3.560 |
Why?
|
| Child | 161 | 2025 | 25712 | 3.420 |
Why?
|
| Environmental Exposure | 14 | 2025 | 246 | 3.320 |
Why?
|
| Texas | 63 | 2025 | 3684 | 3.280 |
Why?
|
| Infant | 103 | 2025 | 13135 | 3.180 |
Why?
|
| Cancer Survivors | 14 | 2025 | 247 | 2.980 |
Why?
|
| Central Nervous System Neoplasms | 11 | 2025 | 216 | 2.960 |
Why?
|
| Neural Tube Defects | 13 | 2023 | 358 | 2.950 |
Why?
|
| Cleft Palate | 9 | 2022 | 154 | 2.810 |
Why?
|
| Polymorphism, Single Nucleotide | 34 | 2025 | 2935 | 2.810 |
Why?
|
| Kidney Neoplasms | 5 | 2025 | 463 | 2.730 |
Why?
|
| Female | 221 | 2025 | 71588 | 2.640 |
Why?
|
| Humans | 307 | 2025 | 133858 | 2.610 |
Why?
|
| Infant, Newborn | 79 | 2025 | 8574 | 2.610 |
Why?
|
| Risk Factors | 88 | 2025 | 11077 | 2.570 |
Why?
|
| Male | 189 | 2025 | 65821 | 2.360 |
Why?
|
| Genome-Wide Association Study | 27 | 2025 | 1872 | 2.310 |
Why?
|
| Child, Preschool | 89 | 2025 | 14776 | 2.310 |
Why?
|
| Case-Control Studies | 58 | 2025 | 3638 | 2.290 |
Why?
|
| Heart Defects, Congenital | 27 | 2025 | 1874 | 2.290 |
Why?
|
| Prenatal Exposure Delayed Effects | 13 | 2025 | 244 | 2.280 |
Why?
|
| Cleft Lip | 7 | 2022 | 133 | 2.200 |
Why?
|
| Adolescent | 102 | 2025 | 20517 | 2.200 |
Why?
|
| Young Adult | 80 | 2025 | 9883 | 2.190 |
Why?
|
| Vehicle Emissions | 5 | 2019 | 20 | 2.180 |
Why?
|
| Pregnancy | 66 | 2025 | 7512 | 2.170 |
Why?
|
| Leukemia, Myeloid, Acute | 8 | 2024 | 569 | 2.160 |
Why?
|
| Leukemia | 6 | 2023 | 380 | 2.140 |
Why?
|
| Folic Acid | 15 | 2024 | 298 | 2.140 |
Why?
|
| Down Syndrome | 13 | 2025 | 230 | 2.120 |
Why?
|
| Hypospadias | 7 | 2022 | 80 | 1.950 |
Why?
|
| Residence Characteristics | 8 | 2024 | 292 | 1.910 |
Why?
|
| Adult | 109 | 2025 | 31926 | 1.890 |
Why?
|
| DNA Methylation | 14 | 2024 | 1146 | 1.880 |
Why?
|
| Prevalence | 38 | 2025 | 2655 | 1.820 |
Why?
|
| Wilms Tumor | 3 | 2025 | 119 | 1.800 |
Why?
|
| Anophthalmos | 5 | 2024 | 24 | 1.800 |
Why?
|
| Maternal Age | 12 | 2025 | 139 | 1.780 |
Why?
|
| Microphthalmos | 5 | 2024 | 60 | 1.780 |
Why?
|
| Congenital Microtia | 3 | 2022 | 24 | 1.700 |
Why?
|
| Neuroblastoma | 6 | 2024 | 539 | 1.680 |
Why?
|
| Air Pollution | 7 | 2025 | 75 | 1.640 |
Why?
|
| Liver Neoplasms | 7 | 2025 | 1410 | 1.600 |
Why?
|
| Benzene | 7 | 2015 | 24 | 1.600 |
Why?
|
| Birth Weight | 7 | 2023 | 352 | 1.570 |
Why?
|
| Premature Birth | 8 | 2025 | 417 | 1.540 |
Why?
|
| Neoplasms, Second Primary | 3 | 2024 | 164 | 1.470 |
Why?
|
| Diabetes, Gestational | 3 | 2022 | 115 | 1.460 |
Why?
|
| Occupational Exposure | 11 | 2020 | 139 | 1.450 |
Why?
|
| Medulloblastoma | 8 | 2022 | 570 | 1.420 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 8 | 2020 | 78 | 1.410 |
Why?
|
| Incidence | 28 | 2025 | 3393 | 1.400 |
Why?
|
| Pregnancy Complications | 8 | 2024 | 547 | 1.390 |
Why?
|
| United States | 55 | 2025 | 11681 | 1.380 |
Why?
|
| Germ-Line Mutation | 7 | 2025 | 368 | 1.370 |
Why?
|
| Thyroid Neoplasms | 3 | 2025 | 255 | 1.360 |
Why?
|
| Abnormalities, Multiple | 6 | 2022 | 976 | 1.340 |
Why?
|
| Hepatoblastoma | 5 | 2024 | 184 | 1.340 |
Why?
|
| Coloboma | 3 | 2024 | 45 | 1.300 |
Why?
|
| Paternal Exposure | 4 | 2025 | 12 | 1.300 |
Why?
|
| Neonatal Screening | 6 | 2024 | 193 | 1.270 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 4 | 2023 | 40 | 1.270 |
Why?
|
| Retinoblastoma | 3 | 2025 | 119 | 1.250 |
Why?
|
| Retinal Neoplasms | 3 | 2025 | 104 | 1.240 |
Why?
|
| Metabolomics | 4 | 2021 | 456 | 1.220 |
Why?
|
| Gastroschisis | 6 | 2020 | 55 | 1.220 |
Why?
|
| Logistic Models | 24 | 2023 | 1908 | 1.220 |
Why?
|
| Health Status Disparities | 5 | 2025 | 246 | 1.180 |
Why?
|
| Odds Ratio | 25 | 2024 | 1337 | 1.180 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 4 | 2023 | 52 | 1.180 |
Why?
|
| Lymphoma | 3 | 2023 | 335 | 1.180 |
Why?
|
| Sarcoma | 3 | 2019 | 210 | 1.150 |
Why?
|
| Spinal Dysraphism | 10 | 2018 | 274 | 1.150 |
Why?
|
| Hodgkin Disease | 2 | 2023 | 298 | 1.150 |
Why?
|
| Live Birth | 12 | 2025 | 70 | 1.130 |
Why?
|
| Particulate Matter | 5 | 2025 | 79 | 1.110 |
Why?
|
| Cerebellar Neoplasms | 6 | 2022 | 461 | 1.110 |
Why?
|
| Exome | 7 | 2025 | 1067 | 1.100 |
Why?
|
| Histiocytosis, Langerhans-Cell | 7 | 2024 | 239 | 1.100 |
Why?
|
| Population Surveillance | 12 | 2023 | 418 | 1.080 |
Why?
|
| Reproductive Techniques, Assisted | 3 | 2024 | 74 | 1.080 |
Why?
|
| Gene-Environment Interaction | 5 | 2019 | 133 | 1.040 |
Why?
|
| Retinoblastoma Binding Proteins | 2 | 2025 | 13 | 1.030 |
Why?
|
| Proportional Hazards Models | 13 | 2025 | 1483 | 1.030 |
Why?
|
| Craniosynostoses | 3 | 2020 | 134 | 1.030 |
Why?
|
| Hazardous Substances | 4 | 2021 | 18 | 1.020 |
Why?
|
| Environmental Health | 2 | 2025 | 15 | 1.010 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2021 | 140 | 1.000 |
Why?
|
| Fertilization in Vitro | 3 | 2025 | 161 | 1.000 |
Why?
|
| Biliary Atresia | 7 | 2023 | 204 | 0.980 |
Why?
|
| Sarcoma, Ewing | 2 | 2024 | 117 | 0.970 |
Why?
|
| Genotype | 22 | 2024 | 2807 | 0.970 |
Why?
|
| Paternal Age | 1 | 2025 | 17 | 0.960 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2025 | 388 | 0.950 |
Why?
|
| Atrazine | 3 | 2013 | 8 | 0.940 |
Why?
|
| Herbicides | 3 | 2013 | 13 | 0.940 |
Why?
|
| Neurodevelopmental Disorders | 3 | 2019 | 529 | 0.920 |
Why?
|
| Bone Neoplasms | 3 | 2024 | 447 | 0.890 |
Why?
|
| Biomarkers, Tumor | 3 | 2025 | 1718 | 0.880 |
Why?
|
| Methotrexate | 7 | 2025 | 355 | 0.870 |
Why?
|
| Neoplasm Proteins | 3 | 2019 | 717 | 0.850 |
Why?
|
| Beckwith-Wiedemann Syndrome | 1 | 2023 | 16 | 0.850 |
Why?
|
| Osteosarcoma | 2 | 2023 | 263 | 0.840 |
Why?
|
| Population Dynamics | 2 | 2015 | 34 | 0.820 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2024 | 1314 | 0.800 |
Why?
|
| Choanal Atresia | 2 | 2012 | 18 | 0.800 |
Why?
|
| Turner Syndrome | 1 | 2023 | 46 | 0.800 |
Why?
|
| Healthcare Disparities | 3 | 2025 | 480 | 0.800 |
Why?
|
| SEER Program | 7 | 2025 | 224 | 0.780 |
Why?
|
| Metabolic Networks and Pathways | 3 | 2019 | 197 | 0.770 |
Why?
|
| Thyroxine | 2 | 2012 | 75 | 0.770 |
Why?
|
| Brain Neoplasms | 6 | 2025 | 1409 | 0.760 |
Why?
|
| Aortic Coarctation | 1 | 2023 | 110 | 0.740 |
Why?
|
| Infertility | 1 | 2022 | 82 | 0.740 |
Why?
|
| Patient Selection | 1 | 2025 | 734 | 0.730 |
Why?
|
| Prognosis | 19 | 2025 | 5071 | 0.730 |
Why?
|
| Genetic Variation | 11 | 2025 | 1621 | 0.730 |
Why?
|
| Clinical Trials as Topic | 2 | 2025 | 1153 | 0.720 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2021 | 52 | 0.710 |
Why?
|
| Obesity | 7 | 2020 | 2410 | 0.710 |
Why?
|
| Mothers | 10 | 2025 | 369 | 0.710 |
Why?
|
| Bone Marrow | 3 | 2021 | 334 | 0.700 |
Why?
|
| Antimetabolites, Antineoplastic | 5 | 2025 | 197 | 0.700 |
Why?
|
| Metabolome | 2 | 2021 | 312 | 0.690 |
Why?
|
| Neuroectodermal Tumors, Primitive | 3 | 2022 | 57 | 0.680 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 933 | 0.660 |
Why?
|
| Neoplasm, Residual | 2 | 2022 | 134 | 0.660 |
Why?
|
| Germ Cells | 5 | 2024 | 203 | 0.640 |
Why?
|
| Telomere Homeostasis | 2 | 2020 | 47 | 0.640 |
Why?
|
| Diacylglycerol Kinase | 1 | 2019 | 15 | 0.630 |
Why?
|
| Sarcoma, Synovial | 3 | 2024 | 22 | 0.630 |
Why?
|
| Air Pollution, Indoor | 2 | 2019 | 33 | 0.630 |
Why?
|
| Emigrants and Immigrants | 1 | 2021 | 153 | 0.630 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2021 | 178 | 0.630 |
Why?
|
| Digestive System Abnormalities | 1 | 2019 | 37 | 0.630 |
Why?
|
| Neurotoxicity Syndromes | 3 | 2025 | 63 | 0.630 |
Why?
|
| Cohort Studies | 15 | 2024 | 5173 | 0.620 |
Why?
|
| Butadienes | 2 | 2015 | 21 | 0.610 |
Why?
|
| Radon | 2 | 2015 | 11 | 0.610 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2025 | 999 | 0.610 |
Why?
|
| Parents | 6 | 2025 | 1058 | 0.610 |
Why?
|
| Molecular Epidemiology | 2 | 2018 | 162 | 0.580 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 397 | 0.560 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2019 | 207 | 0.560 |
Why?
|
| Risk Assessment | 9 | 2022 | 3691 | 0.550 |
Why?
|
| Sex Characteristics | 1 | 2019 | 335 | 0.550 |
Why?
|
| Gestational Age | 7 | 2023 | 1215 | 0.550 |
Why?
|
| Transcription Factors | 6 | 2025 | 2703 | 0.550 |
Why?
|
| Phenotype | 14 | 2024 | 4532 | 0.540 |
Why?
|
| Survival Rate | 10 | 2025 | 2207 | 0.530 |
Why?
|
| Statistics as Topic | 1 | 2017 | 261 | 0.530 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2016 | 25 | 0.530 |
Why?
|
| Hypersensitivity | 2 | 2022 | 198 | 0.520 |
Why?
|
| Survivors | 7 | 2022 | 360 | 0.520 |
Why?
|
| Genetic Testing | 6 | 2025 | 1093 | 0.500 |
Why?
|
| Quantitative Trait Loci | 3 | 2022 | 319 | 0.500 |
Why?
|
| Air Pollutants, Radioactive | 1 | 2015 | 5 | 0.500 |
Why?
|
| Epoxide Hydrolases | 2 | 2013 | 39 | 0.490 |
Why?
|
| Tuberous Sclerosis | 3 | 2024 | 124 | 0.490 |
Why?
|
| Soft Tissue Neoplasms | 4 | 2024 | 128 | 0.490 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 317 | 0.480 |
Why?
|
| Retrospective Studies | 43 | 2025 | 17460 | 0.480 |
Why?
|
| Hydrocarbons, Chlorinated | 2 | 2012 | 15 | 0.480 |
Why?
|
| Family | 6 | 2023 | 588 | 0.470 |
Why?
|
| Anencephaly | 3 | 2013 | 11 | 0.470 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 168 | 0.470 |
Why?
|
| Constriction, Pathologic | 2 | 2012 | 241 | 0.460 |
Why?
|
| Body Mass Index | 6 | 2025 | 1709 | 0.460 |
Why?
|
| Smoking | 4 | 2020 | 1139 | 0.460 |
Why?
|
| Syndrome | 5 | 2021 | 1165 | 0.460 |
Why?
|
| CpG Islands | 6 | 2024 | 347 | 0.450 |
Why?
|
| Risk | 9 | 2024 | 831 | 0.440 |
Why?
|
| Follow-Up Studies | 11 | 2025 | 5505 | 0.440 |
Why?
|
| Haplotypes | 2 | 2013 | 562 | 0.440 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2014 | 32 | 0.440 |
Why?
|
| Epigenesis, Genetic | 5 | 2023 | 774 | 0.430 |
Why?
|
| 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 1 | 2013 | 22 | 0.430 |
Why?
|
| Proteins | 2 | 2019 | 1087 | 0.430 |
Why?
|
| Age Factors | 10 | 2021 | 2975 | 0.430 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2013 | 203 | 0.430 |
Why?
|
| Gastrointestinal Diseases | 1 | 2017 | 361 | 0.430 |
Why?
|
| Environmental Monitoring | 2 | 2015 | 89 | 0.420 |
Why?
|
| Eczema | 1 | 2013 | 30 | 0.420 |
Why?
|
| Urticaria | 1 | 2013 | 22 | 0.420 |
Why?
|
| B-Lymphocytes | 1 | 2016 | 550 | 0.420 |
Why?
|
| Weight Gain | 3 | 2023 | 414 | 0.420 |
Why?
|
| Middle Aged | 23 | 2025 | 29378 | 0.410 |
Why?
|
| Cryptosporidium | 2 | 2014 | 34 | 0.410 |
Why?
|
| Intellectual Disability | 4 | 2023 | 1076 | 0.400 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 1911 | 0.400 |
Why?
|
| GTP Cyclohydrolase | 1 | 2012 | 5 | 0.400 |
Why?
|
| Inhalation Exposure | 2 | 2015 | 38 | 0.400 |
Why?
|
| Limb Deformities, Congenital | 2 | 2025 | 110 | 0.390 |
Why?
|
| Socioeconomic Factors | 6 | 2020 | 919 | 0.390 |
Why?
|
| Air Pollutants, Occupational | 1 | 2012 | 18 | 0.390 |
Why?
|
| Pesticides | 3 | 2017 | 31 | 0.380 |
Why?
|
| Hypoglycemia | 1 | 2013 | 193 | 0.380 |
Why?
|
| Models, Theoretical | 2 | 2015 | 398 | 0.370 |
Why?
|
| Mutation | 9 | 2025 | 6290 | 0.370 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 1354 | 0.370 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 3 | 2023 | 96 | 0.370 |
Why?
|
| Genetic Association Studies | 7 | 2020 | 844 | 0.360 |
Why?
|
| Pregnancy Outcome | 3 | 2021 | 624 | 0.360 |
Why?
|
| Testicular Neoplasms | 2 | 2023 | 135 | 0.360 |
Why?
|
| Genetic Markers | 4 | 2019 | 631 | 0.360 |
Why?
|
| Ebstein Anomaly | 1 | 2011 | 29 | 0.360 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 2123 | 0.350 |
Why?
|
| Thymidylate Synthase | 1 | 2010 | 23 | 0.350 |
Why?
|
| Fertilization | 2 | 2021 | 45 | 0.350 |
Why?
|
| Vaccination | 1 | 2016 | 1011 | 0.340 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 4 | 2017 | 71 | 0.330 |
Why?
|
| Hernia, Umbilical | 2 | 2020 | 42 | 0.320 |
Why?
|
| Censuses | 2 | 2022 | 11 | 0.320 |
Why?
|
| Insulin Resistance | 1 | 2013 | 684 | 0.300 |
Why?
|
| Infant, Small for Gestational Age | 3 | 2025 | 60 | 0.300 |
Why?
|
| Cryptosporidiosis | 1 | 2008 | 44 | 0.290 |
Why?
|
| ROC Curve | 4 | 2020 | 614 | 0.280 |
Why?
|
| Frailty | 2 | 2021 | 131 | 0.280 |
Why?
|
| Overweight | 3 | 2022 | 384 | 0.280 |
Why?
|
| Dog Diseases | 1 | 2008 | 61 | 0.280 |
Why?
|
| Genetic Counseling | 3 | 2024 | 244 | 0.280 |
Why?
|
| Expert Testimony | 1 | 2007 | 37 | 0.280 |
Why?
|
| Bayes Theorem | 6 | 2023 | 315 | 0.280 |
Why?
|
| Policy Making | 1 | 2007 | 62 | 0.270 |
Why?
|
| Radiation Exposure | 2 | 2020 | 49 | 0.270 |
Why?
|
| Surveys and Questionnaires | 9 | 2023 | 3987 | 0.270 |
Why?
|
| Skin Neoplasms | 2 | 2025 | 906 | 0.270 |
Why?
|
| Neoplastic Syndromes, Hereditary | 2 | 2025 | 76 | 0.270 |
Why?
|
| Infant, Low Birth Weight | 3 | 2025 | 176 | 0.270 |
Why?
|
| New York | 3 | 2025 | 73 | 0.270 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 689 | 0.260 |
Why?
|
| Holoprosencephaly | 2 | 2021 | 24 | 0.260 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 648 | 0.250 |
Why?
|
| Dietary Supplements | 4 | 2014 | 498 | 0.250 |
Why?
|
| Epilepsy | 3 | 2024 | 890 | 0.250 |
Why?
|
| Epigenomics | 3 | 2023 | 195 | 0.250 |
Why?
|
| Asthma | 1 | 2013 | 811 | 0.240 |
Why?
|
| Nondisjunction, Genetic | 1 | 2025 | 22 | 0.240 |
Why?
|
| Neurofibromin 2 | 1 | 2025 | 11 | 0.240 |
Why?
|
| Crossing Over, Genetic | 1 | 2025 | 54 | 0.240 |
Why?
|
| Exercise | 2 | 2025 | 877 | 0.240 |
Why?
|
| Neurofibromatoses | 1 | 2025 | 10 | 0.240 |
Why?
|
| Zika Virus Infection | 2 | 2018 | 175 | 0.240 |
Why?
|
| Genome, Human | 4 | 2021 | 1350 | 0.240 |
Why?
|
| Neurofibromatosis 2 | 1 | 2025 | 10 | 0.240 |
Why?
|
| Chromosome Segregation | 1 | 2025 | 67 | 0.240 |
Why?
|
| Portoenterostomy, Hepatic | 3 | 2021 | 58 | 0.240 |
Why?
|
| DiGeorge Syndrome | 2 | 2018 | 82 | 0.240 |
Why?
|
| Leiomyomatosis | 1 | 2025 | 8 | 0.240 |
Why?
|
| North Carolina | 2 | 2025 | 64 | 0.240 |
Why?
|
| SMARCB1 Protein | 1 | 2025 | 48 | 0.230 |
Why?
|
| Laxatives | 1 | 2024 | 9 | 0.230 |
Why?
|
| Trisomy | 1 | 2025 | 112 | 0.230 |
Why?
|
| Massachusetts | 2 | 2025 | 131 | 0.230 |
Why?
|
| Pharmacogenomic Variants | 1 | 2024 | 38 | 0.230 |
Why?
|
| Costello Syndrome | 1 | 2024 | 17 | 0.230 |
Why?
|
| Neurilemmoma | 1 | 2025 | 48 | 0.230 |
Why?
|
| DNA Helicases | 2 | 2024 | 251 | 0.230 |
Why?
|
| Lamin Type A | 1 | 2024 | 13 | 0.230 |
Why?
|
| Parturition | 1 | 2025 | 67 | 0.230 |
Why?
|
| Oil and Gas Fields | 1 | 2024 | 9 | 0.230 |
Why?
|
| Noonan Syndrome | 1 | 2024 | 31 | 0.230 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2015 | 113 | 0.220 |
Why?
|
| Comorbidity | 2 | 2019 | 1613 | 0.220 |
Why?
|
| Neurofibromatosis 1 | 1 | 2024 | 64 | 0.220 |
Why?
|
| Leukemoid Reaction | 1 | 2023 | 2 | 0.210 |
Why?
|
| Constipation | 1 | 2024 | 126 | 0.210 |
Why?
|
| Hydroxyurea | 1 | 2024 | 86 | 0.210 |
Why?
|
| Klinefelter Syndrome | 1 | 2023 | 18 | 0.210 |
Why?
|
| Medically Uninsured | 1 | 2024 | 76 | 0.210 |
Why?
|
| Extremities | 1 | 2023 | 88 | 0.210 |
Why?
|
| Research | 2 | 2022 | 272 | 0.210 |
Why?
|
| Precision Medicine | 2 | 2025 | 356 | 0.210 |
Why?
|
| Salvage Therapy | 1 | 2024 | 202 | 0.200 |
Why?
|
| Mediator Complex | 1 | 2023 | 54 | 0.200 |
Why?
|
| Urban Population | 3 | 2021 | 240 | 0.200 |
Why?
|
| Insurance, Health | 1 | 2024 | 144 | 0.200 |
Why?
|
| Arkansas | 2 | 2020 | 58 | 0.200 |
Why?
|
| Cholangitis | 1 | 2023 | 39 | 0.200 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2014 | 224 | 0.200 |
Why?
|
| Craniospinal Irradiation | 1 | 2023 | 66 | 0.200 |
Why?
|
| Insurance Coverage | 1 | 2024 | 124 | 0.200 |
Why?
|
| Social Class | 2 | 2022 | 205 | 0.200 |
Why?
|
| Cardiovascular Abnormalities | 2 | 2019 | 54 | 0.200 |
Why?
|
| Cranial Irradiation | 2 | 2020 | 72 | 0.200 |
Why?
|
| Rare Diseases | 1 | 2025 | 206 | 0.200 |
Why?
|
| Toluene | 3 | 2013 | 11 | 0.200 |
Why?
|
| Xylenes | 3 | 2013 | 13 | 0.200 |
Why?
|
| Benzene Derivatives | 3 | 2013 | 19 | 0.200 |
Why?
|
| Asparaginase | 1 | 2022 | 48 | 0.190 |
Why?
|
| Prenatal Care | 2 | 2023 | 359 | 0.190 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2014 | 224 | 0.190 |
Why?
|
| Pyloric Stenosis, Hypertrophic | 1 | 2022 | 6 | 0.190 |
Why?
|
| Genomics | 5 | 2025 | 1676 | 0.190 |
Why?
|
| Solvents | 2 | 2012 | 46 | 0.190 |
Why?
|
| Cognition Disorders | 3 | 2020 | 579 | 0.190 |
Why?
|
| Eye Abnormalities | 2 | 2019 | 105 | 0.190 |
Why?
|
| Fetus | 4 | 2022 | 599 | 0.190 |
Why?
|
| Counseling | 1 | 2023 | 240 | 0.190 |
Why?
|
| Linear Models | 3 | 2017 | 723 | 0.190 |
Why?
|
| Monocytes | 2 | 2023 | 361 | 0.190 |
Why?
|
| Disease-Free Survival | 3 | 2019 | 971 | 0.190 |
Why?
|
| Rothmund-Thomson Syndrome | 1 | 2022 | 47 | 0.190 |
Why?
|
| Tooth, Deciduous | 1 | 2021 | 6 | 0.180 |
Why?
|
| RecQ Helicases | 1 | 2022 | 64 | 0.180 |
Why?
|
| Tankyrases | 1 | 2021 | 5 | 0.180 |
Why?
|
| Codon, Nonsense | 2 | 2020 | 140 | 0.180 |
Why?
|
| Medical Oncology | 1 | 2023 | 244 | 0.180 |
Why?
|
| Cities | 2 | 2014 | 51 | 0.180 |
Why?
|
| Mouth Abnormalities | 1 | 2021 | 15 | 0.180 |
Why?
|
| gamma-Glutamyl Hydrolase | 1 | 2021 | 10 | 0.180 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 1 | 2021 | 13 | 0.180 |
Why?
|
| Carcinoma | 1 | 2024 | 322 | 0.180 |
Why?
|
| Trisomy 13 Syndrome | 1 | 2021 | 20 | 0.180 |
Why?
|
| Teratology | 1 | 2020 | 1 | 0.180 |
Why?
|
| Frameshift Mutation | 2 | 2020 | 199 | 0.180 |
Why?
|
| Educational Status | 3 | 2018 | 293 | 0.180 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2021 | 27 | 0.180 |
Why?
|
| Pancreatitis | 1 | 2022 | 144 | 0.180 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2022 | 117 | 0.180 |
Why?
|
| Body Size | 1 | 2021 | 69 | 0.180 |
Why?
|
| Human Growth Hormone | 1 | 2021 | 78 | 0.180 |
Why?
|
| Early Detection of Cancer | 1 | 2025 | 413 | 0.180 |
Why?
|
| Pregnancy, Multiple | 1 | 2021 | 48 | 0.170 |
Why?
|
| Stress, Psychological | 2 | 2016 | 600 | 0.170 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2021 | 40 | 0.170 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2020 | 15 | 0.170 |
Why?
|
| Antineoplastic Agents | 5 | 2022 | 1850 | 0.170 |
Why?
|
| Scimitar Syndrome | 1 | 2021 | 52 | 0.170 |
Why?
|
| Aged | 14 | 2024 | 21722 | 0.170 |
Why?
|
| Forecasting | 1 | 2022 | 376 | 0.170 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2021 | 563 | 0.170 |
Why?
|
| Prospective Studies | 5 | 2024 | 6654 | 0.170 |
Why?
|
| Anemia, Sickle Cell | 1 | 2024 | 341 | 0.170 |
Why?
|
| Optic Atrophies, Hereditary | 1 | 2020 | 17 | 0.170 |
Why?
|
| Proton Therapy | 1 | 2022 | 151 | 0.170 |
Why?
|
| Hypertension, Portal | 1 | 2021 | 81 | 0.170 |
Why?
|
| HLA Antigens | 2 | 2019 | 253 | 0.170 |
Why?
|
| COUP Transcription Factor I | 1 | 2020 | 91 | 0.170 |
Why?
|
| Epidemiological Monitoring | 2 | 2018 | 62 | 0.170 |
Why?
|
| Poverty Areas | 2 | 2021 | 32 | 0.170 |
Why?
|
| Dried Blood Spot Testing | 1 | 2020 | 27 | 0.160 |
Why?
|
| Biomarkers | 3 | 2021 | 3422 | 0.160 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2019 | 12 | 0.160 |
Why?
|
| Acute Disease | 2 | 2022 | 1189 | 0.160 |
Why?
|
| Membrane Proteins | 3 | 2023 | 1607 | 0.160 |
Why?
|
| Telomere-Binding Proteins | 1 | 2020 | 46 | 0.160 |
Why?
|
| Carbohydrate Metabolism | 1 | 2019 | 58 | 0.160 |
Why?
|
| Models, Genetic | 3 | 2018 | 789 | 0.160 |
Why?
|
| Computational Biology | 2 | 2021 | 888 | 0.160 |
Why?
|
| Growth Disorders | 1 | 2021 | 221 | 0.160 |
Why?
|
| Pulmonary Veins | 1 | 2021 | 166 | 0.160 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 178 | 0.160 |
Why?
|
| Sweden | 1 | 2019 | 55 | 0.160 |
Why?
|
| Bilirubin | 1 | 2020 | 131 | 0.160 |
Why?
|
| Abdominal Wall | 1 | 2019 | 34 | 0.160 |
Why?
|
| DNA-Binding Proteins | 5 | 2020 | 2161 | 0.160 |
Why?
|
| Housing | 2 | 2018 | 54 | 0.160 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 282 | 0.160 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 311 | 0.150 |
Why?
|
| Wearable Electronic Devices | 1 | 2021 | 108 | 0.150 |
Why?
|
| Congresses as Topic | 2 | 2018 | 187 | 0.150 |
Why?
|
| Lactase | 1 | 2019 | 41 | 0.150 |
Why?
|
| Musculoskeletal Abnormalities | 1 | 2019 | 71 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2019 | 118 | 0.150 |
Why?
|
| Hematopoiesis | 1 | 2021 | 229 | 0.150 |
Why?
|
| Aged, 80 and over | 7 | 2024 | 7204 | 0.150 |
Why?
|
| Chromosome Aberrations | 2 | 2023 | 626 | 0.150 |
Why?
|
| Rural Population | 1 | 2021 | 282 | 0.150 |
Why?
|
| Metals, Heavy | 1 | 2019 | 24 | 0.150 |
Why?
|
| Seasons | 1 | 2020 | 330 | 0.150 |
Why?
|
| Dendritic Cells | 3 | 2023 | 448 | 0.150 |
Why?
|
| Autism Spectrum Disorder | 2 | 2021 | 421 | 0.150 |
Why?
|
| Medical History Taking | 1 | 2019 | 118 | 0.150 |
Why?
|
| Cisplatin | 2 | 2017 | 287 | 0.150 |
Why?
|
| Occupational Diseases | 2 | 2016 | 75 | 0.150 |
Why?
|
| Liver Diseases | 1 | 2023 | 388 | 0.150 |
Why?
|
| Preconception Care | 2 | 2018 | 16 | 0.150 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 204 | 0.150 |
Why?
|
| Zika Virus | 2 | 2018 | 151 | 0.150 |
Why?
|
| Histocompatibility | 1 | 2018 | 50 | 0.150 |
Why?
|
| Problem Behavior | 1 | 2019 | 41 | 0.150 |
Why?
|
| Celiac Disease | 1 | 2019 | 73 | 0.150 |
Why?
|
| Data Mining | 1 | 2018 | 58 | 0.150 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2018 | 24 | 0.150 |
Why?
|
| Optic Nerve Glioma | 1 | 2018 | 22 | 0.150 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 3740 | 0.140 |
Why?
|
| Williams Syndrome | 1 | 2018 | 42 | 0.140 |
Why?
|
| Nervous System Malformations | 1 | 2019 | 131 | 0.140 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 279 | 0.140 |
Why?
|
| Histocompatibility Testing | 1 | 2018 | 151 | 0.140 |
Why?
|
| Intestinal Atresia | 1 | 2017 | 20 | 0.140 |
Why?
|
| Water Pollution | 1 | 2017 | 2 | 0.140 |
Why?
|
| Smad6 Protein | 1 | 2017 | 8 | 0.140 |
Why?
|
| Diagnostic Imaging | 2 | 2022 | 317 | 0.140 |
Why?
|
| Drug Discovery | 1 | 2019 | 182 | 0.140 |
Why?
|
| Drinking Water | 1 | 2017 | 17 | 0.140 |
Why?
|
| Early Diagnosis | 1 | 2018 | 198 | 0.140 |
Why?
|
| Language Development Disorders | 1 | 2019 | 179 | 0.140 |
Why?
|
| Prader-Willi Syndrome | 1 | 2018 | 69 | 0.140 |
Why?
|
| Esophageal Atresia | 1 | 2017 | 52 | 0.140 |
Why?
|
| Tracheoesophageal Fistula | 1 | 2017 | 48 | 0.140 |
Why?
|
| Smith-Magenis Syndrome | 1 | 2018 | 105 | 0.140 |
Why?
|
| Leukocytes | 1 | 2018 | 224 | 0.140 |
Why?
|
| p21-Activated Kinases | 1 | 2017 | 58 | 0.140 |
Why?
|
| Databases, Factual | 3 | 2017 | 1240 | 0.140 |
Why?
|
| Treatment Outcome | 9 | 2023 | 13010 | 0.140 |
Why?
|
| History, 21st Century | 1 | 2018 | 279 | 0.140 |
Why?
|
| Alleles | 6 | 2021 | 1706 | 0.140 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 2016 | 18 | 0.130 |
Why?
|
| Hematologic Neoplasms | 1 | 2020 | 294 | 0.130 |
Why?
|
| Vitamin B 12 | 1 | 2017 | 63 | 0.130 |
Why?
|
| Postoperative Complications | 2 | 2020 | 3229 | 0.130 |
Why?
|
| Europe | 1 | 2017 | 384 | 0.130 |
Why?
|
| Promoter Regions, Genetic | 2 | 2021 | 1414 | 0.130 |
Why?
|
| Delayed Diagnosis | 1 | 2018 | 135 | 0.130 |
Why?
|
| Amino Acids | 1 | 2019 | 688 | 0.130 |
Why?
|
| Cytokines | 1 | 2023 | 1396 | 0.130 |
Why?
|
| Micronutrients | 1 | 2017 | 73 | 0.130 |
Why?
|
| Mexico | 1 | 2016 | 190 | 0.130 |
Why?
|
| Hospitals | 1 | 2019 | 429 | 0.130 |
Why?
|
| Delivery of Health Care | 2 | 2022 | 679 | 0.130 |
Why?
|
| Charcot-Marie-Tooth Disease | 1 | 2018 | 237 | 0.130 |
Why?
|
| Health Surveys | 2 | 2018 | 258 | 0.130 |
Why?
|
| Melanoma | 1 | 2023 | 974 | 0.130 |
Why?
|
| Whole Genome Sequencing | 1 | 2017 | 327 | 0.120 |
Why?
|
| Meningomyelocele | 2 | 2017 | 255 | 0.120 |
Why?
|
| Geographic Information Systems | 1 | 2015 | 41 | 0.120 |
Why?
|
| Ear Diseases | 1 | 2015 | 21 | 0.120 |
Why?
|
| Geography | 1 | 2015 | 124 | 0.120 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2017 | 365 | 0.120 |
Why?
|
| Thailand | 1 | 2015 | 44 | 0.120 |
Why?
|
| Lymphangioma, Cystic | 1 | 2015 | 18 | 0.120 |
Why?
|
| Lymphangioma | 1 | 2015 | 25 | 0.120 |
Why?
|
| Gastrointestinal Tract | 1 | 2017 | 243 | 0.120 |
Why?
|
| Defoliants, Chemical | 1 | 2014 | 1 | 0.120 |
Why?
|
| 2,4,5-Trichlorophenoxyacetic Acid | 1 | 2014 | 1 | 0.120 |
Why?
|
| 2,4-Dichlorophenoxyacetic Acid | 1 | 2014 | 2 | 0.120 |
Why?
|
| Vietnam Conflict | 1 | 2014 | 9 | 0.120 |
Why?
|
| Polychlorinated Dibenzodioxins | 1 | 2014 | 6 | 0.120 |
Why?
|
| Workplace | 1 | 2015 | 82 | 0.120 |
Why?
|
| Colon | 1 | 2017 | 380 | 0.110 |
Why?
|
| Immunocompetence | 1 | 2014 | 35 | 0.110 |
Why?
|
| Superoxide Dismutase | 1 | 2015 | 187 | 0.110 |
Why?
|
| Iron-Regulatory Proteins | 1 | 2014 | 5 | 0.110 |
Why?
|
| Seizures | 1 | 2020 | 889 | 0.110 |
Why?
|
| Birth Order | 1 | 2014 | 9 | 0.110 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2014 | 45 | 0.110 |
Why?
|
| Algorithms | 4 | 2024 | 1732 | 0.110 |
Why?
|
| Flecainide | 1 | 2014 | 23 | 0.110 |
Why?
|
| Thoracic Neoplasms | 2 | 2024 | 38 | 0.110 |
Why?
|
| Digoxin | 1 | 2014 | 44 | 0.110 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 408 | 0.110 |
Why?
|
| Astrocytoma | 1 | 2015 | 113 | 0.110 |
Why?
|
| Magnesium Oxide | 1 | 2013 | 2 | 0.110 |
Why?
|
| Reduced Folate Carrier Protein | 1 | 2013 | 20 | 0.110 |
Why?
|
| Propranolol | 1 | 2014 | 130 | 0.110 |
Why?
|
| Age Distribution | 1 | 2015 | 444 | 0.110 |
Why?
|
| Psychometrics | 2 | 2016 | 684 | 0.110 |
Why?
|
| DNA | 1 | 2020 | 1675 | 0.110 |
Why?
|
| Platinum | 1 | 2013 | 13 | 0.110 |
Why?
|
| Developmental Disabilities | 1 | 2019 | 733 | 0.110 |
Why?
|
| Baths | 1 | 2013 | 16 | 0.110 |
Why?
|
| Eating | 1 | 2016 | 387 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 510 | 0.110 |
Why?
|
| Microcephaly | 1 | 2016 | 347 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 1406 | 0.110 |
Why?
|
| Swimming Pools | 1 | 2013 | 12 | 0.100 |
Why?
|
| Animals | 9 | 2024 | 36364 | 0.100 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2014 | 111 | 0.100 |
Why?
|
| Ependymoma | 1 | 2015 | 174 | 0.100 |
Why?
|
| Ferredoxin-NADP Reductase | 1 | 2013 | 11 | 0.100 |
Why?
|
| Metal Nanoparticles | 1 | 2013 | 59 | 0.100 |
Why?
|
| Skin Diseases | 1 | 2014 | 135 | 0.100 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2013 | 44 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2013 | 104 | 0.100 |
Why?
|
| Alcohol Drinking | 2 | 2013 | 387 | 0.100 |
Why?
|
| Hydrocarbons | 1 | 2012 | 9 | 0.100 |
Why?
|
| Dementia | 2 | 2008 | 485 | 0.100 |
Why?
|
| Disorders of Sex Development | 1 | 2013 | 72 | 0.100 |
Why?
|
| Occupations | 1 | 2012 | 22 | 0.100 |
Why?
|
| Endocrine Disruptors | 1 | 2013 | 53 | 0.100 |
Why?
|
| Glutathione Transferase | 1 | 2013 | 163 | 0.100 |
Why?
|
| Metabolic Detoxication, Phase I | 1 | 2012 | 10 | 0.100 |
Why?
|
| Metabolic Detoxication, Phase II | 1 | 2012 | 15 | 0.100 |
Why?
|
| Bone Diseases | 1 | 2012 | 44 | 0.100 |
Why?
|
| Military Personnel | 1 | 2014 | 201 | 0.100 |
Why?
|
| Gene Frequency | 3 | 2020 | 778 | 0.100 |
Why?
|
| Neural Tube | 1 | 2012 | 45 | 0.100 |
Why?
|
| Poverty | 1 | 2015 | 435 | 0.090 |
Why?
|
| Pregnancy Trimester, First | 1 | 2012 | 123 | 0.090 |
Why?
|
| Gene Expression | 2 | 2017 | 1614 | 0.090 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 3752 | 0.090 |
Why?
|
| Siblings | 2 | 2024 | 198 | 0.090 |
Why?
|
| Public Health | 2 | 2018 | 287 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2021 | 1140 | 0.090 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 2656 | 0.090 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2010 | 9 | 0.090 |
Why?
|
| Creatinine | 2 | 2023 | 423 | 0.090 |
Why?
|
| Patient Compliance | 1 | 2014 | 479 | 0.090 |
Why?
|
| Iron | 1 | 2013 | 303 | 0.090 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 2292 | 0.080 |
Why?
|
| Spine | 2 | 2021 | 147 | 0.080 |
Why?
|
| Isoenzymes | 1 | 2010 | 231 | 0.080 |
Why?
|
| Cognition | 3 | 2022 | 815 | 0.080 |
Why?
|
| Hypertension | 1 | 2018 | 1391 | 0.080 |
Why?
|
| Anus Diseases | 1 | 2009 | 14 | 0.080 |
Why?
|
| Rectal Diseases | 1 | 2009 | 21 | 0.080 |
Why?
|
| Cardiomyopathies | 1 | 2014 | 514 | 0.080 |
Why?
|
| Nodal Protein | 1 | 2009 | 18 | 0.080 |
Why?
|
| Mutation, Missense | 3 | 2023 | 927 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 2 | 2014 | 1631 | 0.080 |
Why?
|
| Glucose | 1 | 2013 | 923 | 0.080 |
Why?
|
| Electronics | 2 | 2022 | 47 | 0.080 |
Why?
|
| DNA Repair | 1 | 2012 | 630 | 0.070 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2008 | 153 | 0.070 |
Why?
|
| Amnesia | 1 | 2007 | 18 | 0.070 |
Why?
|
| Peritoneal Neoplasms | 1 | 2008 | 53 | 0.070 |
Why?
|
| Ikaros Transcription Factor | 2 | 2019 | 32 | 0.070 |
Why?
|
| Causality | 2 | 2021 | 94 | 0.070 |
Why?
|
| Recombinant Proteins | 2 | 2021 | 1439 | 0.070 |
Why?
|
| Global Health | 1 | 2012 | 620 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2023 | 1253 | 0.070 |
Why?
|
| DNA Primers | 1 | 2008 | 671 | 0.070 |
Why?
|
| Dogs | 1 | 2008 | 800 | 0.070 |
Why?
|
| Disease Progression | 4 | 2015 | 2239 | 0.070 |
Why?
|
| DNA Copy Number Variations | 2 | 2025 | 1022 | 0.060 |
Why?
|
| Brain | 2 | 2021 | 3217 | 0.060 |
Why?
|
| Bacterial Infections | 1 | 2009 | 325 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2014 | 2026 | 0.060 |
Why?
|
| Neoadjuvant Therapy | 1 | 2008 | 404 | 0.060 |
Why?
|
| Minnesota | 1 | 2025 | 181 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2021 | 1485 | 0.060 |
Why?
|
| Chromosome Deletion | 2 | 2019 | 664 | 0.060 |
Why?
|
| Hemochromatosis Protein | 2 | 2015 | 23 | 0.060 |
Why?
|
| Meiosis | 1 | 2025 | 115 | 0.060 |
Why?
|
| Health Policy | 1 | 2007 | 232 | 0.060 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2008 | 849 | 0.060 |
Why?
|
| Nuclear Proteins | 2 | 2024 | 1334 | 0.060 |
Why?
|
| Markov Chains | 1 | 2025 | 99 | 0.060 |
Why?
|
| Software | 2 | 2020 | 737 | 0.060 |
Why?
|
| Antisickling Agents | 1 | 2024 | 18 | 0.060 |
Why?
|
| Recurrence | 2 | 2020 | 1467 | 0.060 |
Why?
|
| Splenic Diseases | 1 | 2024 | 31 | 0.060 |
Why?
|
| Canada | 1 | 2025 | 343 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2021 | 1596 | 0.060 |
Why?
|
| Splenomegaly | 1 | 2024 | 33 | 0.060 |
Why?
|
| Liver | 2 | 2023 | 1867 | 0.060 |
Why?
|
| Sperm Injections, Intracytoplasmic | 1 | 2024 | 45 | 0.050 |
Why?
|
| Splenectomy | 1 | 2024 | 63 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2016 | 830 | 0.050 |
Why?
|
| United Kingdom | 1 | 2024 | 237 | 0.050 |
Why?
|
| ras Proteins | 1 | 2024 | 146 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 196 | 0.050 |
Why?
|
| Uterine Neoplasms | 1 | 2025 | 112 | 0.050 |
Why?
|
| Base Sequence | 1 | 2008 | 3171 | 0.050 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2023 | 65 | 0.050 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2023 | 95 | 0.050 |
Why?
|
| Neural Crest | 1 | 2023 | 56 | 0.050 |
Why?
|
| Histone Acetyltransferases | 1 | 2024 | 317 | 0.050 |
Why?
|
| Intelligence | 1 | 2023 | 108 | 0.050 |
Why?
|
| Laparoscopy | 1 | 2008 | 513 | 0.050 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2022 | 34 | 0.050 |
Why?
|
| Age of Onset | 1 | 2024 | 635 | 0.050 |
Why?
|
| Maternal-Fetal Exchange | 2 | 2013 | 85 | 0.050 |
Why?
|
| Hyperbilirubinemia | 1 | 2022 | 42 | 0.050 |
Why?
|
| Interleukin-12 | 1 | 2023 | 122 | 0.050 |
Why?
|
| Loss of Function Mutation | 1 | 2023 | 159 | 0.050 |
Why?
|
| Stomach Neoplasms | 1 | 2008 | 559 | 0.050 |
Why?
|
| Hypokalemia | 1 | 2022 | 41 | 0.050 |
Why?
|
| HEK293 Cells | 2 | 2015 | 814 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 1790 | 0.050 |
Why?
|
| Methylation | 1 | 2022 | 231 | 0.050 |
Why?
|
| Stillbirth | 1 | 2022 | 103 | 0.050 |
Why?
|
| Social Adjustment | 1 | 2022 | 80 | 0.050 |
Why?
|
| Choroid | 1 | 2021 | 43 | 0.050 |
Why?
|
| Protons | 1 | 2022 | 98 | 0.050 |
Why?
|
| Demography | 1 | 2022 | 247 | 0.050 |
Why?
|
| Sex Factors | 2 | 2016 | 1384 | 0.050 |
Why?
|
| Machine Learning | 1 | 2025 | 330 | 0.050 |
Why?
|
| Drug Utilization Review | 1 | 2021 | 33 | 0.050 |
Why?
|
| Time Factors | 3 | 2018 | 6583 | 0.050 |
Why?
|
| GATA1 Transcription Factor | 1 | 2021 | 9 | 0.050 |
Why?
|
| Homozygote | 1 | 2023 | 560 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2022 | 438 | 0.040 |
Why?
|
| Infertility, Male | 1 | 2024 | 289 | 0.040 |
Why?
|
| Anal Canal | 1 | 2021 | 83 | 0.040 |
Why?
|
| Information Services | 1 | 2020 | 22 | 0.040 |
Why?
|
| Organizations | 1 | 2020 | 16 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2022 | 176 | 0.040 |
Why?
|
| Foot | 1 | 2021 | 65 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 418 | 0.040 |
Why?
|
| Cloaca | 1 | 2020 | 15 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 1071 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2022 | 252 | 0.040 |
Why?
|
| Genitalia, Male | 1 | 2020 | 39 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2021 | 444 | 0.040 |
Why?
|
| Anus, Imperforate | 1 | 2020 | 20 | 0.040 |
Why?
|
| Vena Cava, Inferior | 1 | 2021 | 104 | 0.040 |
Why?
|
| Hand | 1 | 2021 | 107 | 0.040 |
Why?
|
| Thyroid Diseases | 1 | 2020 | 33 | 0.040 |
Why?
|
| Alzheimer Disease | 1 | 2008 | 874 | 0.040 |
Why?
|
| Liver Transplantation | 2 | 2020 | 1125 | 0.040 |
Why?
|
| Chromatin | 1 | 2023 | 609 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2023 | 407 | 0.040 |
Why?
|
| GATA3 Transcription Factor | 1 | 2019 | 39 | 0.040 |
Why?
|
| Trachea | 1 | 2021 | 212 | 0.040 |
Why?
|
| Esophagus | 1 | 2021 | 233 | 0.040 |
Why?
|
| Heterozygote | 1 | 2022 | 718 | 0.040 |
Why?
|
| Fatigue | 1 | 2020 | 203 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2020 | 149 | 0.040 |
Why?
|
| Adiposity | 1 | 2020 | 208 | 0.040 |
Why?
|
| Maternal Inheritance | 1 | 2018 | 14 | 0.040 |
Why?
|
| Introns | 1 | 2020 | 313 | 0.040 |
Why?
|
| Musculoskeletal Diseases | 1 | 2019 | 60 | 0.040 |
Why?
|
| Ear | 1 | 2018 | 27 | 0.040 |
Why?
|
| United States Public Health Service | 1 | 2018 | 5 | 0.040 |
Why?
|
| Child Development | 1 | 2021 | 287 | 0.040 |
Why?
|
| Language Development | 1 | 2019 | 36 | 0.040 |
Why?
|
| Central Nervous System Diseases | 1 | 2019 | 110 | 0.040 |
Why?
|
| Folic Acid Deficiency | 1 | 2019 | 55 | 0.040 |
Why?
|
| Point Mutation | 1 | 2020 | 360 | 0.040 |
Why?
|
| Reference Values | 1 | 2020 | 742 | 0.040 |
Why?
|
| Morbidity | 1 | 2019 | 255 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 739 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 2024 | 699 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2019 | 259 | 0.040 |
Why?
|
| Body Composition | 1 | 2021 | 563 | 0.040 |
Why?
|
| RNA, Long Noncoding | 1 | 2021 | 246 | 0.040 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2018 | 51 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 202 | 0.040 |
Why?
|
| Proteome | 1 | 2020 | 281 | 0.040 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 187 | 0.040 |
Why?
|
| Retina | 1 | 2021 | 503 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2025 | 1334 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 95 | 0.040 |
Why?
|
| Penetrance | 1 | 2018 | 111 | 0.040 |
Why?
|
| Cesarean Section | 1 | 2021 | 399 | 0.040 |
Why?
|
| Eye Diseases | 1 | 2019 | 138 | 0.040 |
Why?
|
| Risk Adjustment | 1 | 2017 | 58 | 0.030 |
Why?
|
| Water Supply | 1 | 2017 | 27 | 0.030 |
Why?
|
| Guatemala | 1 | 2017 | 63 | 0.030 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2018 | 94 | 0.030 |
Why?
|
| Pandemics | 1 | 2025 | 1196 | 0.030 |
Why?
|
| Washington | 1 | 2017 | 35 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2018 | 238 | 0.030 |
Why?
|
| Chromosome Duplication | 1 | 2018 | 148 | 0.030 |
Why?
|
| Haploinsufficiency | 1 | 2019 | 274 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 2020 | 621 | 0.030 |
Why?
|
| Recommended Dietary Allowances | 1 | 2017 | 24 | 0.030 |
Why?
|
| Arizona | 1 | 2016 | 26 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2019 | 440 | 0.030 |
Why?
|
| Cardiovascular Diseases | 2 | 2020 | 2082 | 0.030 |
Why?
|
| Women, Working | 1 | 2016 | 9 | 0.030 |
Why?
|
| Diet Records | 1 | 2017 | 76 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 349 | 0.030 |
Why?
|
| Ozone | 1 | 2016 | 21 | 0.030 |
Why?
|
| Florida | 1 | 2016 | 79 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2020 | 400 | 0.030 |
Why?
|
| Mice | 3 | 2023 | 18881 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2019 | 505 | 0.030 |
Why?
|
| Neutrophils | 1 | 2019 | 401 | 0.030 |
Why?
|
| Pre-Eclampsia | 1 | 2018 | 226 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 319 | 0.030 |
Why?
|
| Minority Groups | 1 | 2018 | 255 | 0.030 |
Why?
|
| Cataract | 1 | 2018 | 229 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2016 | 230 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2016 | 159 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 1976 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2015 | 13 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1488 | 0.030 |
Why?
|
| Reading | 1 | 2016 | 84 | 0.030 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2019 | 453 | 0.030 |
Why?
|
| Information Storage and Retrieval | 1 | 2015 | 65 | 0.030 |
Why?
|
| Learning | 1 | 2019 | 378 | 0.030 |
Why?
|
| Workload | 1 | 2016 | 151 | 0.030 |
Why?
|
| Utah | 1 | 2015 | 81 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2018 | 1124 | 0.030 |
Why?
|
| Hearing Loss | 1 | 2017 | 214 | 0.030 |
Why?
|
| Posture | 1 | 2015 | 157 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2022 | 786 | 0.030 |
Why?
|
| Agent Orange | 1 | 2014 | 3 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2016 | 244 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 1595 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2015 | 327 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 2158 | 0.030 |
Why?
|
| Research Design | 1 | 2019 | 754 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2009 | 1387 | 0.030 |
Why?
|
| History, Ancient | 1 | 2014 | 56 | 0.030 |
Why?
|
| Erdheim-Chester Disease | 1 | 2014 | 27 | 0.030 |
Why?
|
| Databases as Topic | 1 | 2014 | 77 | 0.030 |
Why?
|
| Xanthogranuloma, Juvenile | 1 | 2014 | 33 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 1126 | 0.030 |
Why?
|
| Mannose-Binding Lectins | 1 | 2014 | 26 | 0.030 |
Why?
|
| Histiocytosis, Sinus | 1 | 2014 | 34 | 0.030 |
Why?
|
| Neuropsychological Tests | 2 | 2008 | 983 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2018 | 570 | 0.030 |
Why?
|
| Kidney | 1 | 2021 | 1410 | 0.030 |
Why?
|
| CD11c Antigen | 1 | 2014 | 40 | 0.030 |
Why?
|
| Gases | 1 | 2013 | 20 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2014 | 112 | 0.030 |
Why?
|
| Lectins, C-Type | 1 | 2014 | 76 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2014 | 224 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2014 | 90 | 0.030 |
Why?
|
| Crystallization | 1 | 2013 | 90 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 2014 | 119 | 0.030 |
Why?
|
| Magnetics | 1 | 2013 | 42 | 0.030 |
Why?
|
| X-Ray Diffraction | 1 | 2013 | 106 | 0.030 |
Why?
|
| Habits | 1 | 2013 | 26 | 0.030 |
Why?
|
| Nanotechnology | 1 | 2013 | 52 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2013 | 136 | 0.030 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2013 | 153 | 0.030 |
Why?
|
| Lung | 1 | 2021 | 1556 | 0.030 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2018 | 484 | 0.030 |
Why?
|
| Magnesium | 1 | 2013 | 127 | 0.030 |
Why?
|
| Income | 1 | 2014 | 141 | 0.030 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2013 | 31 | 0.030 |
Why?
|
| Xenobiotics | 1 | 2013 | 29 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2013 | 300 | 0.030 |
Why?
|
| Betaine | 1 | 2013 | 23 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 542 | 0.030 |
Why?
|
| Temperature | 1 | 2013 | 330 | 0.030 |
Why?
|
| Acculturation | 1 | 2013 | 69 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 1006 | 0.030 |
Why?
|
| Choline | 1 | 2013 | 55 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 324 | 0.020 |
Why?
|
| Mass Screening | 1 | 2019 | 832 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2013 | 160 | 0.020 |
Why?
|
| Vitamin B Complex | 1 | 2013 | 45 | 0.020 |
Why?
|
| Mexican Americans | 1 | 2014 | 207 | 0.020 |
Why?
|
| Vinblastine | 1 | 2012 | 58 | 0.020 |
Why?
|
| Health Behavior | 1 | 2015 | 402 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2014 | 366 | 0.020 |
Why?
|
| Motor Activity | 1 | 2015 | 537 | 0.020 |
Why?
|
| Pulmonary Valve Stenosis | 1 | 2012 | 40 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2014 | 369 | 0.020 |
Why?
|
| Prednisone | 1 | 2012 | 288 | 0.020 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2012 | 88 | 0.020 |
Why?
|
| Encephalocele | 1 | 2011 | 50 | 0.020 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2012 | 134 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 823 | 0.020 |
Why?
|
| Fetal Death | 1 | 2011 | 121 | 0.020 |
Why?
|
| Transposition of Great Vessels | 1 | 2012 | 133 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1490 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 4800 | 0.020 |
Why?
|
| Health Promotion | 1 | 2014 | 402 | 0.020 |
Why?
|
| Oxygen | 1 | 2013 | 577 | 0.020 |
Why?
|
| Growth Differentiation Factor 1 | 1 | 2009 | 4 | 0.020 |
Why?
|
| Pediatrics | 1 | 2019 | 1216 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2008 | 3064 | 0.020 |
Why?
|
| Quality of Life | 1 | 2019 | 2132 | 0.020 |
Why?
|
| Esophagogastric Junction | 1 | 2008 | 34 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 1188 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2009 | 676 | 0.020 |
Why?
|
| Aortic Valve Stenosis | 1 | 2012 | 346 | 0.020 |
Why?
|
| Body Weight | 1 | 2012 | 1034 | 0.020 |
Why?
|
| Ligands | 1 | 2009 | 572 | 0.020 |
Why?
|
| Medical Records | 1 | 2008 | 194 | 0.020 |
Why?
|
| Gastrectomy | 1 | 2008 | 103 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 783 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 2009 | 269 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2009 | 486 | 0.020 |
Why?
|
| Hospitalization | 1 | 2014 | 1884 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 896 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 1315 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2009 | 2785 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 3970 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2009 | 4896 | 0.010 |
Why?
|